Gold prices recently broke above $2,950, continuing a strong upward trend throughout 2024. Click to read.

Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s shares closed last Friday at $1.20. Discover the ...

As a result, William Blair lowered its delivery estimates for the first quarter from 418,000 to 350,000 and for the full year from 1.94 million to 1.68 million. Despite these concerns, the firm ...

On Tuesday, William Blair initiated coverage on Immunic Inc. (NASDAQ:IMUX) with an Outperform rating, highlighting the potential of its relapse-remitting multiple sclerosis (RMS) therapy ...

William Blair also issued estimates for Five Below’s FY2027 earnings at $4.48 EPS. Get Five Below alerts: A number of other research analysts also recently issued reports on FIVE.

William Blair also issued estimates for Five Below’s Q2 2026 earnings at $0.48 EPS, Q3 2026 earnings at $0.17 EPS and Q4 2026 earnings at $3.24 EPS. Get Five Below alerts: Several other analysts ...

Five Below, Inc. FIVE reported fourth-quarter fiscal 2024 results, wherein both top and bottom lines beat the Zacks Consensus Estimate. Net sales increased and earnings decreased year over year.